Description: Biocodex develops and markets drugs for patients with severe orphan diseases and has set up a dedicated business unit.
Biocodex is a multinational pharmaceutical company, with 20 subsidiaries and 74 partners
Biocodex develops and markets drugs for patients with severe orphan diseases. In the early 1990’s, our R&D center in Compiègne (France) found and developed an anti-epileptic drug indicated for a newly discovered rare and severe epileptic disorder: Dravet Syndrome. Since then, we have been committed to raising awareness on rare epilepsies alongside healthcare professionals, patients and caregivers. Our aim is to provide effective, innovative products and services that help lighten the disease burden for pati
After receiving marketing authorization in Europe in 2007, Biocodex’s DIACOMIT® (stiripentol) has been approved in many countries around the world for the treatment of a severe form of epilepsy that starts in infancy: Dravet Syndrome.